AGL vs. PINC, PGNY, SHC, AMPH, RXRX, DNA, DCPH, AMRX, NEO, and KROS
Should you be buying agilon health stock or one of its competitors? The main competitors of agilon health include Premier (PINC), Progyny (PGNY), Sotera Health (SHC), Amphastar Pharmaceuticals (AMPH), Recursion Pharmaceuticals (RXRX), Ginkgo Bioworks (DNA), Deciphera Pharmaceuticals (DCPH), Amneal Pharmaceuticals (AMRX), NeoGenomics (NEO), and Keros Therapeutics (KROS). These companies are all part of the "medical" sector.
Premier (NASDAQ:PINC) and agilon health (NYSE:AGL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.
In the previous week, agilon health had 6 more articles in the media than Premier. MarketBeat recorded 13 mentions for agilon health and 7 mentions for Premier. agilon health's average media sentiment score of 0.23 beat Premier's score of 0.08 indicating that Premier is being referred to more favorably in the media.
74.4% of Premier shares are owned by institutional investors. 0.9% of Premier shares are owned by company insiders. Comparatively, 3.2% of agilon health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Premier has a net margin of 6.01% compared to Premier's net margin of -5.67%. agilon health's return on equity of 11.71% beat Premier's return on equity.
Premier presently has a consensus target price of $23.50, indicating a potential upside of 19.53%. agilon health has a consensus target price of $9.32, indicating a potential upside of 72.30%. Given Premier's stronger consensus rating and higher possible upside, analysts plainly believe agilon health is more favorable than Premier.
Premier received 563 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 69.07% of users gave Premier an outperform vote while only 52.69% of users gave agilon health an outperform vote.
Premier has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, agilon health has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
Premier has higher earnings, but lower revenue than agilon health. agilon health is trading at a lower price-to-earnings ratio than Premier, indicating that it is currently the more affordable of the two stocks.
Summary
Premier beats agilon health on 11 of the 18 factors compared between the two stocks.
Get agilon health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
agilon health Competitors List
Related Companies and Tools
